Lung Cancer | Specialty

Immunotherapy Leads the Way in Lung Cancer, but Creates Complex Treatment Decisions

November 27th 2020

Joshua Reuss, MD, discusses the lung cancer armamentarium, the role of immunotherapy combinations, and the significance of biomarkers.

PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC

November 25th 2020

Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.

TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market

November 24th 2020

November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.

Dr. Chaft on the Rationale for the OPAL Trial in EGFR+ NSCLC

November 23rd 2020

Jamie E. Chaft, MD, discusses the rationale behind the OPAL trial in EGFR-mutant non–small cell lung cancer.

Oxnard on Opening the Door for Precision Medicine in Lung Cancer

November 23rd 2020

In our exclusive interview, Dr. Oxnard explained how precision medicine has affected the treatment landscape of lung cancer, discussed the current capabilities of liquid biopsy, and forecasted the future of precision oncology in the field.

Sugemalimab/Chemo Combo Elicits Clinically Meaningful PFS Benefit in Metastatic NSCLC

November 21st 2020

November 21, 2020 - The addition of sugemalimab to chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit in the frontline treatment of patients with metastatic non–small cell lung cancer versus placebo plus chemotherapy.

Dr. Perol on EGFR TKI/Chemotherapy Combinations in Advanced EGFR+ NSCLC

November 21st 2020

Maurice Perol, MD, discusses combination regimens comprised of chemotherapy and EGFR TKIs in the treatment of patients with EGFR-mutated advanced non–small cell lung cancer, as investigated in the OPAL trial presented during the ESMO Asia Virtual Congress 2020.

Dr. Chaft on the Next Steps of Osimertinib Research in EGFR+ NSCLC

November 20th 2020

Jamie E. Chaft, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps of osimertinib research in EGFR-mutant non–small cell lung cancer.

Dr. Tsuboi on Findings From the Phase 3 ADAURA Trial in EGFR+ NSCLC

November 20th 2020

Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses findings from the phase 3 ADAURA trial in EGFR-mutant non–small cell lung cancer.

Osimertinib Plus Chemotherapy Is Well Tolerated in Frontline EGFR+ NSCLC

November 20th 2020

November 20, 2020 - Osimertinib in combination with platinum plus pemetrexed was well tolerated in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer.